Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本患者临床症状既无明显胸痛,也无腹痛与腹胀,而
进行性加重的呼吸困难为表
。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本患者临床症状既无明显胸痛,也无腹痛与腹胀,而
进行性加重的呼吸困难为表
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发
问题,欢迎向我们指正。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本例患者临床症状既无明,也无腹
与腹胀,而以进行性加重的呼吸困难为表
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发问题,欢迎向我们指正。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本例临床症状既无明显胸痛,也无腹痛与腹胀,而以
加重的呼吸困难为表
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并硬化的慢
丙
(CHC)
接受α干扰素包括派罗欣治疗时存在
功能失代偿和死亡风险。
声明:以上例句、词分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发
问题,欢迎向我们指正。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本例患者临床症状既无明显胸痛,也无腹痛与腹胀,而以进行性加重的呼吸困难为表。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性类均由互联网资源自动生成,部
过人工审核,其表达内容亦不代表本软件的观点;若发
问题,欢迎向我们指正。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本例患者临床症状既无明显胸痛,也无腹痛与腹胀,而以进行性加重的呼吸困难为表。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失和死亡风险。
声明:以上例句、词性分类均由互联网资生成,部分未经过人工审核,其表达内容亦不
表本软件的观点;若发
问题,欢迎向我们指正。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本例患者临床症状显胸痛,也
腹痛与腹胀,而以进行性加重的呼吸困难为表
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗肝功能失代偿和死亡风险。
声:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发
问题,欢迎向我们指正。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本患者临床症状既无明显胸痛,也无腹痛与腹胀,而
进行性加重的呼吸困难为表
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发
问题,欢迎向我们指正。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本例患者临床症状既无明显胸痛,也无腹痛与腹胀,而以进行性加重的呼吸困难为表。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能代偿和死亡风险。
声明:以上例句、词性分类均由互源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发
问题,欢迎向我们指正。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本例患者临床症状既无明显胸痛,也无腹痛与腹胀,而以进行性加重的呼吸困难为表。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代和死亡风险。
声明:以上例句、词性分类均网资源自动生成,部分未经过人工审核,其表达内容亦
代表本软件的观点;若发
问题,欢迎向我们指正。